Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-institutional retrospective cohort study.

ABSTRACT:

Background

For unresectable stage III non-small cell lung cancer (NSCLC), the standard regimen is definitive concurrent chemoradiotherapy (CRT) followed by consolidation immunotherapy. We investigated whether incorporating induction immunochemotherapy enhances the efficacy.

Materials and methods

From June 2018 to December 2022, 294 patients with unresectable stage III NSCLC were included, who did (162, I-CRT-I group) or did not (132, CRT-I group) receive induction immunochemotherapy, followed by definitive CRT and consolidation immunotherapy. Propensity score matching (PSM) adjusted for potential confounding variables. Overall survival (OS), progression-free survival (PFS), recurrence pattern, and safety were evaluated.

Results

After PSM, 206 patients (103 in each gro

SUBMITTER: Fu Z 

PROVIDER: S-EPMC12350322 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature